Sintilimab With Pemigatinib in Patients With PD-L1-positive and FGFR Mutated Advanced Non-small Cell Lung Cancer

NCT05004974 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Advanced Non Small Cell Lung Cancer

Interventions

DRUG: Sintilimab
DRUG: Pemigatinib

Sponsor

The Fourth Affiliated Hospital of Zhejiang University School of Medicine

Collaborators

[object Object]